Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Exenatide × Other × Clear all

Phase

Phase 3 2 Phase 4 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Polycystic Ovary Syndrome 1 Obesity 1 Fatty Liver 1

Interventions

tegaserod 1 semaglutide 1 penclomedine 1 aluminum hydroxide, magnesium hydroxide, drug combination 1 Thioctic Acid 1 Tablets 1 Radiation 1 Metformin 1 Megestrol Acetate 1 Low-Level Light Therapy 1 Lidocaine 1 Letrozole 1 LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 1 Exercise 1 Exenatide 1 Diphenhydramine 1 Buspirone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02157974 2024-06-04

APPLE

University of Colorado, Denver

Phase 2/3 Completed

92 enrolled 17 charts

Fatty Liver, Obesity, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡